Four Research Peptides, One Repair Network

The short version

Agility Peptide is a research desk, not a store. It collects what the published literature actually says about four peptides that recur in conversations about recovery and tissue repair: BPC-157, TB-500, GHK-Cu, and KLOW. A peptide is a short chain of amino acids — the building blocks that make up proteins, only far smaller. Each of these has been studied because it appears to engage one or more nodes of the body's repair machinery: growing new blood vessels into damaged tissue, helping cells migrate toward a wound, rebuilding collagen and elastin scaffolding, or suppressing the inflammatory signaling that stalls healing.

This guide does one job: it reports, in plain language and with citations, what each peptide was tested on, in which species, and how far that evidence actually reaches. Most stops well short of humans. None of these is an approved medicine. We do not sell anything, we do not give medical advice, and we never list a human dose.

What are research peptides?

Proteins — collagen in a tendon, an enzyme in the gut lining, a signaling hormone — are long chains of amino acids folded into a specific shape. A peptide is a much shorter chain of the same building blocks, sometimes only three or four residues long. Because they are small and specific, peptides can interact with particular receptors on cell surfaces, switching certain biological processes on or off.

A research peptide is one that has been synthesized and studied — in cell cultures, in animals, occasionally in early human pilots — but has not been approved by a regulator as a medicine. Suppliers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in people are usually unestablished. When this site reports a number it reports it exactly as the study did — studied at X in [species] — never as a recommendation. Where a peptide is derived from a natural protein, that lineage is noted, because it is often the clue to what the peptide does.

How these four fit into recovery research

The four peptides on this desk address repair from different angles, which is the reason they sit together.

• BPC-157 is the lead. A fifteen-amino-acid peptide derived from a gastric-juice protein, its healing effects in animals are most consistently linked to angiogenesis — new vessel growth into injured tissue via the VEGFR2-Akt-eNOS pathway ^[4]. Three decades of rodent work span tendon, gut, muscle and nerve repair; only three tiny human pilots exist as of the most recent reviews ^[2].
• TB-500 carries the actin-binding motif of thymosin beta-4, a natural protein that helps cells reorganize their internal skeleton and migrate toward a wound ^[10]. The critical caveat: most published efficacy data used full-length thymosin beta-4, not the short fragment sold as TB-500 ^[8].
• GHK-Cu is a copper-carrying tripeptide that signals dermal fibroblasts to rebuild collagen and elastin scaffolding, and it holds the most human evidence of the four — though chiefly from topical skin studies ^[16].
• KLOW is a co-formulated blend of all four components: KPV, GHK-Cu, BPC-157, and TB-500. It is the only entry on this desk that has never been tested as a combination; every claim about synergy is a mechanistic extrapolation from the single-component literature ^[8][1].

Together they sketch repair from four angles: vascular supply, cell migration, matrix scaffolding, and inflammation. Read each compound page, or compare these peptides side by side.

A note on how this desk reads the literature

Agility Peptide is a cross-referenced literature digest. Each compound page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a shared references list that aggregates every source across the site. Where evidence is thin, single-lab, or preclinical, the page says so directly — that caution is part of the record, not an asterisk. We describe research findings and the cited cautions that come with them. We do not recommend, prescribe, or sell. The goal is an accurate, data-forward map of what is known — including where the evidence is solid and where it is still mostly promise.